Cabaletta Bio, Inc. Common Stock (CABA) Stock Price
CABAStock
$3.12+108.00%52W
Market Cap$528.98M
P/E—
PEG Ratio—
Div yield—
Beta3.46
CABA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-17.10%
Price vs S&P 500 (4W)14.44%
VGM Score57.96
CABA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.34 | -$0.34 | +0.76%(+$0.00) | |
| Q1 2026 | -$0.39 | -$0.39 | -0.47%(-$0.00) | |
| Q4 2025 | -$0.47 | -$0.40 | +14.12%(+$0.07) | |
| Q3 2025 | -$0.46 | -$0.44 | +3.88%(+$0.02) | |
| Q2 2025 | -$0.61 | -$0.73 | -19.35%(-$0.12) |
CABA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.19
4.19
4.19
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CABACabaletta Bio, Inc. Common Stock | — | — | C | $3.12 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Cabaletta Bio, Inc. Common Stock
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary CAART technology selectively eliminates disease-causing B cells while preserving normal B cells, offering the potential for deep and durable therapeutic effects. The company's CABA platform encompasses multiple strategies applicable across a broad range of autoimmune indications.